2652 — CF PharmTech Income Statement
0.000.00%
Last trade - 00:00- HK$15.56bn
- HK$15.31bn
- CNY607.75m
Annual income statement for CF PharmTech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 349 | 556 | 608 |
| Cost of Revenue | |||
| Gross Profit | 267 | 458 | 491 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 420 | 534 | 587 |
| Operating Profit | -70.5 | 22.7 | 21 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -70.6 | 22.4 | 19.2 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -49.4 | 31.7 | 21.1 |
| Net Income Before Extraordinary Items | |||
| Net Income | -49.4 | 31.7 | 21.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -49.4 | 31.7 | 21.1 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.119 | 0.078 | 0.088 |